This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Association Between COVID-19 Mortality and ICU Admission Rates and Prior History of Angiotensin-Converting Enzyme or Angiotensin Receptor Blockers Use Among Hospitalized COVID-19 Patients with Hypertension in Michigan. (preprint)
authorea preprints; 2023.
Preprint
in English
| PREPRINT-AUTHOREA PREPRINTS | ID: ppzbmed-10.22541.au.167508191.11360548.v1
ABSTRACT
Abstract Importance There are conflicting data regarding the safety of the use of Angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers (ACEI/ARBs ) medications in hypertensive patients who are susceptible to COVID-19. Objective:
Our study assesses the association between COVID-19 severity and mortality and the use of ACEI/ARBs among hospitalized patients with hypertension. Research design, setting andparticipants:
This was a retrospective cohort study. Using the EPIC system of Beaumont Health, we identified 5490 patients with COVID-19 who were admitted to the eight Beaumont hospitals. After excluding subjects who have no hypertension and those with missing data, we included 2129 COVID-19 patients who have hypertension. Logistic regression and Cox proportional hazard models were used to analyze the association history of ACEI/ARBs use, ICU admission rate and COVID-19 mortality. Exposure Using of ACEI/ARBs as documented in the medical records before admission to the hospitals. Mainoutcome:
30 days COVID-19 mortality and ICU admission rates .Results:
There were 1281 subjects (60%) with prior ACEI/ARBs use and 848 subjects ( 40%) with no ACEI/ARBs use. There was no significant association between ICU admission and use of ACEI/ARBs (odds ratio was 0.95, 95% CI [0.76, 1.19] and p-value was 0.6). Although the unadjusted logistic regression model demonstrated a statistically significant association between history of use of ACEI/ARBs and COVID-19 mortality (odds ratio= 1.31, 95% CI [1.05, 1.66], p-value= 0.02), the adjusted logistic regression model failed to show this statistically significant association (odds ratio= 1.20, 95% CI [0.93, 1.54], p-value= 0.14). Moreover, we were not able to reveal a statistically significant association between 30 days COVID-19 survival and prior use of ACEI/ARBs in the adjusted Cox-proportional hazard model (Hazard ratio (HR) = 1.11, 95% CI [0.91, 1.40], p-value =0.14).Conclusion:
In a large retrospective study, we conclude that there was no statistically significant association between prior history of ACEI/ARBs use and COVID-19 ICU admission rates or mortality in hypertensive patients hospitalized with COVID-19.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-AUTHOREA PREPRINTS
Language:
English
Year:
2023
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS